{"entity":{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","aka":[],"tldr":"Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib.","summary":"Komal Jhaveri led EMBER-3, which showed the oral SERD imlunestrant plus abemaciclib improves progression-free survival in ER-positive advanced breast cancer after aromatase inhibitors, and was a lead investigator on INAVO120 (inavolisib for PIK3CA-mutant disease). She heads endocrine therapy research at MSKCC and runs early-phase trials of degraders and PI3K pathway agents.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD"}],"tags":["breast","endocrine","early-phase"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy","protac-degrader"],"targets":["estrogen-receptor","pik3ca"],"drugs":["inavolisib","palbociclib","abemaciclib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["ember-3","inavo120"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Endocrine Therapy Research, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["HR-positive breast cancer","Oral SERDs","PI3K/AKT pathway","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD"}],"papers":[{"title":"Imlunestrant with or without abemaciclib in advanced breast cancer (EMBER-3)","journal":"NEJM","year":2025,"doi":"10.1056/NEJMoa2410858"},{"title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (INAVO120)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2404625"}]},"route":"/people/komal-jhaveri/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/"},{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/"}]}}